Cardiff Oncology, Inc. (NASDAQ: CRDF) reported Q4 EPS of ($0.93), $0.66 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $480 thousand versus the consensus estimate of $50 thousand.

For earnings history and earnings-related data on Cardiff Oncology, Inc. (CRDF) click here.